IQVIA Holdings Management

Management criteria checks 3/4

IQVIA Holdings' CEO is Ari Bousbib, appointed in Oct 2016, has a tenure of 7.5 years. total yearly compensation is $29.15M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 0.73% of the company’s shares, worth $310.52M. The average tenure of the management team and the board of directors is 3.7 years and 7.5 years respectively.

Key information

Ari Bousbib

Chief executive officer

US$29.2m

Total compensation

CEO salary percentage	6.2%
CEO tenure	7.5yrs
CEO ownership	0.7%
Management average tenure	3.7yrs
Board average tenure	7.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ari Bousbib's remuneration changed compared to IQVIA Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$29m	US$2m	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$1b
Dec 31 2022	US$30m	US$2m	US$1b
Sep 30 2022	n/a	n/a	US$1b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	US$29m	US$2m	US$966m
Sep 30 2021	n/a	n/a	US$767m
Jun 30 2021	n/a	n/a	US$607m
Mar 31 2021	n/a	n/a	US$409m
Dec 31 2020	US$26m	US$2m	US$279m
Sep 30 2020	n/a	n/a	US$176m
Jun 30 2020	n/a	n/a	US$132m
Mar 31 2020	n/a	n/a	US$215m
Dec 31 2019	US$22m	US$2m	US$191m
Sep 30 2019	n/a	n/a	US$244m
Jun 30 2019	n/a	n/a	US$247m
Mar 31 2019	n/a	n/a	US$248m
Dec 31 2018	US$16m	US$2m	US$259m
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$38m	US$2m	US$1b

Compensation vs Market: Ari's total compensation ($USD29.15M) is above average for companies of similar size in the UK market ($USD5.62M).

Compensation vs Earnings: Ari's compensation has been consistent with company performance over the past year.

CEO

Ari Bousbib (62 yo)

7.5yrs

Tenure

US$29,151,752

Compensation

Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 03, 2016 and also served as its President. He is Director of IQVIA Holdings Inc since October 03, 2016. H...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ari Bousbib	CEO & Chairman	7.5yrs	US$29.15m	0.73% $ 310.5m
Ronald Bruehlman	Executive VP & CFO	3.7yrs	US$8.56m	0.023% $ 9.7m
Eric Sherbet	Executive VP	6.1yrs	US$3.97m	0.011% $ 4.7m
W. Staub	President of Research & Development Solutions	less than a year	US$1.93m	0.0085% $ 3.6m
Kevin Knightly	President of Corporate Strategy & Enterprise Networks	1.5yrs	US$3.52m	0.00036% $ 153.9k
Keriann Cherofsky	Senior VP	1.7yrs	no data	0.00030% $ 128.3k
Jim Berkshire	Executive Vice President of Global Technology & Operations	less than a year	no data	no data
Jeffrey Spaeder	Senior VP	no data	no data	no data
Kerri Joseph	SVP of Investment Relation & Treasury	less than a year	no data	no data
Trudy Stein	Chief Human Resources Officer & Executive VP	7.5yrs	no data	no data
Cynthia Verst	President of Design & Delivery Innovation	12.8yrs	no data	no data
Andrea Spannheimer	Global Head of Real-World & Late Phase Research	8.5yrs	no data	no data

3.7yrs

Average Tenure

61yo

Average Age

Experienced Management: 0JDM's management team is considered experienced (3.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ari Bousbib	CEO & Chairman	7.5yrs	US$29.15m	0.73% $ 310.5m
John Danhakl	Independent Director	7.5yrs	US$319.93k	0.015% $ 6.6m
John Connaughton	Independent Director	16.3yrs	no data	no data
John Leonard	Independent Lead Director	9.2yrs	US$367.43k	0.0070% $ 3.0m
Leslie Morris	Independent Director	2.3yrs	US$309.93k	0.0011% $ 483.1k
Colleen Goggins	Independent Director	6.8yrs	US$339.93k	0.0056% $ 2.4m
Todd Sisitsky	Independent Director	7.5yrs	no data	no data
Sheila Stamps	Independent Director	2.3yrs	US$312.46k	0.0011% $ 483.1k
James Fasano	Independent Director	7.5yrs	US$304.93k	0.00058% $ 248.0k
Carol Burt	Independent Director	5.2yrs	US$342.43k	0.0033% $ 1.4m

7.5yrs

Average Tenure

63.5yo

Average Age

Experienced Board: 0JDM's board of directors are considered experienced (7.5 years average tenure).

IQVIA Holdings Management

Management criteria checks 3/4

Key information

Recent management updates

Insider recently sold US$3.5m worth of stock

IQVIA Holdings Inc., Annual General Meeting, Apr 16, 2024

Insider recently sold US$1.3m worth of stock

IQVIA Holdings Inc. Appoints Richard Staub III President of Research & Development Solutions

Insider recently sold US$4.2m worth of stock

Insider recently sold US$1.2m worth of stock

Recent updates

IQVIA Holdings Inc. to Report Q1, 2024 Results on May 02, 2024

Insider recently sold US$3.5m worth of stock

IQVIA Holdings Inc., Annual General Meeting, Apr 16, 2024

Insider recently sold US$1.3m worth of stock

Full year 2023 earnings released: EPS: US$7.39 (vs US$5.82 in FY 2022)

IQVIA Holdings Inc. Provides Earnings Guidance for the Full Year of 2024

IQVIA Holdings Inc. to Report Q4, 2023 Results on Feb 14, 2024

IQVIA Holdings Inc. Provides Financial Guidance for the Fourth Quarter and Full-Year of 2023

Third quarter 2023 earnings released: EPS: US$1.66 (vs US$1.52 in 3Q 2022)

IQVIA Holdings Inc. to Report Q3, 2023 Results on Nov 01, 2023

IQVIA Holdings Inc. Appoints Richard Staub III President of Research & Development Solutions

Insider recently sold US$4.2m worth of stock

IQVIA Holdings Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Second quarter 2023 earnings released: EPS: US$1.61 (vs US$1.36 in 2Q 2022)

IQVIA Holdings Inc. to Report Q2, 2023 Results on Aug 01, 2023

IQVIA Launches RIM Smart Labeling to Deliver Intelligence-Driven Approach for Global Label Management

Insider recently sold US$1.2m worth of stock

First quarter 2023 earnings released: EPS: US$1.56 (vs US$1.71 in 1Q 2022)

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Insider recently sold US$1.0m worth of stock

Full year 2022 earnings released: EPS: US$5.82 (vs US$5.05 in FY 2021)

IQVIA Holdings Inc. Provides Revenue Guidance for the Fiscal Year 2023

IQVIA Holdings Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023

IQVIA Holdings Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: EPS: US$1.52 (vs US$1.36 in 3Q 2021)

Iqvia Holdings Inc. Announces Resignation of Ronald A. Rittenmeyer as Member of the Board of Directors and Chairman of the Leadership Development and Compensation Committee

IQVIA Announces its Decentralized Clinical Trial (DCT) Program Receives GDPR Compliance Validation from TRUSTArc

IQVIA Holdings Inc. Announces New Evidence That Decentralized Clinical Trials (DCT) Deliver Measurable Benefits for Patients, Sites and Sponsors

GSK plc and IQVIA launch Vaccine Track

IQVIA Holdings Inc. Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$1.36 (vs US$0.91 in 2Q 2021)

IQVIA Holdings Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2022

IQVIA Holdings Inc. to Report Q2, 2022 Results on Jul 21, 2022

IQVIA Appoints Christina Mack as Chief Scientific Officer of Real World Solutions, Effective from July 7, 2022

First quarter 2022 earnings released: EPS: US$1.71 (vs US$1.11 in 1Q 2021)

IQVIA Holdings Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2022

IQVIA Holdings Inc. to Report Q1, 2022 Results on Apr 27, 2022

IQVIA Holdings Inc. Selects to Support EMA’S DARWIN EU Coordination Centre Initiative

IQVIA Holdings Inc., Annual General Meeting, Apr 12, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IQVIA Holdings Inc. Provides Financial Guidance for the First Quarter and Full Year 2022

IQVIA Holdings Inc. to Report Q4, 2021 Results on Feb 15, 2022

Independent Director recently bought US$2.7m worth of stock

IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Services Unit

Third quarter 2021 earnings released: EPS US$1.36 (vs US$0.53 in 3Q 2020)

IQVIA Launches New A.I.-Powered MI Contact Center for Life Sciences

Insufficient new directors

Second quarter 2021 earnings released: EPS US$0.91 (vs US$0.12 loss in 2Q 2020)

IQVIA Launches the Clinical Data Analytics Suite to Enable Smarter, Faster Clinical Trials

IQVIA Announces That Mischaracterizes Nature of Recent Procedural E-Discovery Ruling in Veeva Systems Antitrust Case Against IQVIA

Iqvia Announces Connected Intelligence

IQVIA Holdings Inc. Provides Earnings Guidance for the Second Quarter of 2021

First quarter 2021 earnings released: EPS US$1.11 (vs US$0.43 in 1Q 2020)

IQVIA Collaborates with Janssen Research & Development on Their Investigational Covid-19 Vaccine Trials

IQVIA Holdings Inc., Annual General Meeting, Apr 13, 2021

IQVIA Holdings Inc. Raises Earnings Guidance for the Full Year of 2021

Full year 2020 earnings released: EPS US$1.46 (vs US$0.98 in FY 2019)

Revenue beats expectations

New 90-day high: US$194

IQVIA Holdings Inc. to Report Q4, 2020 Results on Feb 10, 2021

Laboratoires Théa Selects Iqvia Oce and Onekey to Accelerate Its Global Digital Transformation

Independent Director recently bought US$11m worth of stock

IQVIA and Servier Collaborate to Reinvent Clinical Development

Independent Director recently sold US$7.1m worth of stock

IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

IQVIA Joins U.S. Food and Drug Administration to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project